Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.311 -0.069 (-1.28%)
Delayed Quote Updated: 11:08 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alvotech Completes $100 Million Convertible Bond Private Placement
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
News headline image
Why Shares of Alvotech Are Jumping Friday ↗
The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback. 
Via The Motley Fool
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
News headline image
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating RH, Alvotech, and TriplePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses to Inquire About Securities Class Action Investigation - ALVO, ALVOW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
From Alvotech
Via GlobeNewswire
News headline image
BJ's Wholesale, Kingsoft Cloud, Zoom Video And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For May 18, 2023 ↗
Companies Reporting Before The Bell • Lightspeed Commerce (NYSE:LSPD) is projected to report quarterly loss at $0.04 per share on revenue of $248.01 million. 
Via Benzinga
News headline image
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.